New trends in clinical trials—between complexity and the need for renewal

Authors

  • Celeste Cagnazzo S.C. Oncoematologia Pediatrica – AOU Città della Salute e della Scienza Presidio Infantile Regina Margherita, Turin - Italy https://orcid.org/0000-0003-4055-3139

DOI:

https://doi.org/10.33393/ao.2022.2437

Keywords:

Clinical trials, European regulations, Clinical trial guidelines

Downloads

Download data is not yet available.

References

Vose JM, Levit LA, Hurley P, et al. Addressing administrative and regulatory burden in cancer clinical trials: summary of a stakeholder survey and workshop hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. J Clin Oncol. 2016;34(31):3796-3802. https://doi.org/10.1200/JCO.2016.69.6781 PMID:27601549 DOI: https://doi.org/10.1200/JCO.2016.69.6781

European Commission. Directive 2001/20/EC of the European Parliament and of the Council. Official Journal of the European Union; 2001. Online https://ec.europa.eu/health/system/files/2016-11/dir_2001_20_en_0.pdf. Accessed May 2022.

European Commission. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official Journal of the European Union; 2014. Online https://ec.europa.eu/health/system/files/2016-11/reg_2014_536_en_0.pdf. Accessed May 2022.

Getz KA, Campo RA. Trial watch: Trends in clinical trial design complexity. Nat Rev Drug Discov. 2017;16(5):307. https://doi.org/10.1038/nrd.2017.65 PMID: 28417986 DOI: https://doi.org/10.1038/nrd.2017.65

Getz KA. Rising clinical trial complexity continues to vex drug developers. Online https://www.fiercebiotech.com/biotech/rising-clinical-trial-complexity-continues-to-vex-drug-developers. Accessed May 2022.

Gobbini E, Pilotto S, Pasello G, et al. Effect of contract research organization bureaucracy in clinical trial management: a model from lung cancer. Clin Lung Cancer. 2018;19(2):191-198. https://doi.org/10.1016/j.cllc.2017.10.012 PMID: 29153968 DOI: https://doi.org/10.1016/j.cllc.2017.10.012

Gehring M, Taylor RS, Mellody M, et al. Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study). BMJ Open. 2013;3(11):e002957. https://doi.org/10.1136/bmjopen-2013-002957 PMID:24240138 DOI: https://doi.org/10.1136/bmjopen-2013-002957

Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a more competitive Italy in clinical research: the survey of attitudes towards trial sites in Europe (The SAT-EU Study). Epidemiol Biostat Public Health. 2015;12(1). https://doi.org/10.2427/10246

Cagnazzo C. [Implementation of the European regulation 536/2014 in Italy: the never-ending story.]. Recenti Prog Med. 2022;113(5):299-304. https://doi.org/10.1701/3803.37891 PMID: 35587551

European Commission. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016. Online https://op.europa.eu/en/publication-detail/-/publication/3e485e15-11bd-11e6-ba9a-01aa75ed71a1. Accessed May 2022.

Cagnazzo C. The thin border between individual and collective ethics: the downside of GDPR. Lancet Oncol. 2021;22(11):1494-1496. https://doi.org/10.1016/S1470-2045(21)00526-X PMID: 34735806 DOI: https://doi.org/10.1016/S1470-2045(21)00526-X

Casali PG; European Society for Medical Oncology (ESMO) Switzerland. Risks of the new EU Data Protection Regulation: an ESMO position paper endorsed by the European oncology community. Ann Oncol. 2014;25(8):1458-1461. https://doi.org/10.1093/annonc/mdu218PMID:25063817 DOI: https://doi.org/10.1093/annonc/mdu218

von Niederhäusern B, Fabbro T, Pauli-Magnus C. The role of Clinical Trial Units in investigator- and industry-initiated research projects. Swiss Med Wkly. 2015;145:w14161. https://doi.org/10.4414/smw.2015.14161 PMID:26134324 DOI: https://doi.org/10.4414/smw.2015.14161

Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11(1):78. https://doi.org/10.1186/1745-6215-11-78 PMID:20626885 DOI: https://doi.org/10.1186/1745-6215-11-78

Baer AR, Zon R, Devine S, Lyss AP. The clinical research team. J Oncol Pract. 2011;7(3):188-192. https://doi.org/10.1200/JOP.2011.000276 PMID:21886502 DOI: https://doi.org/10.1200/JOP.2011.000276

Marchesi E, Cagnazzo C, Quattrini I, et al. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res. 2017;7(1):4. https://doi.org/10.1186/s13569-017-0068-4 PMID:28261443 DOI: https://doi.org/10.1186/s13569-017-0068-4

Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol. 2003;21(22):4145-4150. https://doi.org/10.1200/JCO.2003.08.156PMID:14559889 DOI: https://doi.org/10.1200/JCO.2003.08.156

Cagnazzo C, Testoni S, Guarrera AS, et al. [Clinical research coordinators: a crucial resource]. Recenti Prog Med. 2019;110(2):65-67. https://doi.org/10.1701/3112.31000 PMID:30843530

Cagnazzo C, Guarrera A, Cenna R, et al. [Clinical research: enough players to get out there?]. Recenti Prog Med. 2019;110(6):285-291. https://doi.org/10.1701/3182.31609 PMID: 31282484

Horwitz RI. Complexity and contradiction in clinical trial research. Am J Med. 1987;82(3):498-510. https://doi.org/10.1016/0002-9343(87)90450-5 PMID:3548349 DOI: https://doi.org/10.1016/0002-9343(87)90450-5

Cagnazzo C, Fagioli F. [Bureaucracy gives way to science. What good the pandemic has left.]. Recenti Prog Med. 2020;111(10):565-567. https://doi.org/10.1701/3453.34414 PMID: 33078004

Cagnazzo C, Besse MG, Manfellotto D, et al. Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future? Tumori. 2021;107(1):6-11. https://doi.org/10.1177/0300891620977916 PMID:33297885 DOI: https://doi.org/10.1177/0300891620977916

TransCelerate. Beyond COVID-19: Modernizing Clinical Trial Conduct. Online https://www.transceleratebiopharmainc.com/initiatives/modernizing-clinical-trial-conduct/. Accessed May 2022.

Lorusso D, Ray-Coquard I, Oaknin A, Banerjee S. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? ESMO Open. 2020;5(5). https://doi.org/10.1136/esmoopen-2020-000924 PMID: 33051193 DOI: https://doi.org/10.1136/esmoopen-2020-000924

Rogers A, De Paoli G, Subbarayan S, et al; Trials@Home Consortium. A systematic review of methods used to conduct decentralised clinical trials. Br J Clin Pharmacol. 2022;88(6):2843-2862. https://doi.org/10.1111/bcp.15205 PMID:34961991 DOI: https://doi.org/10.1111/bcp.15205

Coyle J, Rogers A, Copland R, et al. Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. Br J Clin Pharmacol. 2022;88(3):1031-1042. https://doi.org/10.1111/bcp.15003 PMID: 34296777 DOI: https://doi.org/10.1111/bcp.15003

Mowlem FD, Tenaerts P, Gwaltney C, Oakley-Girvan I. Regulatory acceptance of patient-reported outcome (PRO) data from bring-your-own-device (BYOD) solutions to support medical product labeling claims : let's share the success stories to move the industry forward. Ther Innov Regul Sci. 2022;56(4):531-535. https://doi.org/10.1007/s43441-022-00412-1 PMID: 35534774 DOI: https://doi.org/10.1007/s43441-022-00412-1

Published

2022-06-21

How to Cite

Cagnazzo, C. (2022). New trends in clinical trials—between complexity and the need for renewal. AboutOpen, 9(1), 42–44. https://doi.org/10.33393/ao.2022.2437
Received 2022-06-07
Accepted 2022-06-07
Published 2022-06-21

Metrics